New weekly shot shows promise for obesity – but It's early days
NCT ID NCT06857617
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called MET097, given as a weekly injection, to see if it is safe and helps with weight loss in adults who are overweight or obese but otherwise healthy. About 120 participants will receive either MET097 or a placebo for up to 12 weeks, with some exploring a once-monthly dose. The goal is to measure weight change and how the drug behaves in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MET097 (a biologic injection)
What this could lead to
If successful, this could lead to a new once-weekly or even once-monthly injection to help people with obesity lose weight.
What could go wrong
This is an early Phase 1/2 trial with only 120 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site MET097 23-101-001
Overland Park, Kansas, 66212, United States
-
Research Site MET097 23-101-002
Anaheim, California, 92801, United States
-
Research Site MET097 23-101-003
Cypress, California, 90630, United States